Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of ca...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lung Cancer (Auckl)
Autores principales: Zhu, Viola W, Schrock, Alexa B, Bosemani, Thangavijayan, Benn, Bryan S, Ali, Siraj M, Ou, Sai-Hong Ignatius
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234987/
https://ncbi.nlm.nih.gov/pubmed/30519133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S186804
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares